Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:17 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe Thrombocytopenia
NCT04543279 · Washington University School of Medicine · PHASE2 · terminated · last registry update 2023-12-15 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Low accrual” | – | Registry record, Washington University School of Medicine |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against SYK within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-11-05Results posted on the registry: NEAT ID Foundation, Fostamatinib + Placebo (NCT05593770)
- 2024-09-19Results posted on the registry: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Fostamatinib 100 mg bid and Paclitaxel + Fostamatinib 150 mg bid and Paclitaxel (NCT03246074)
- 2024-08-07Results posted on the registry: Kronos Bio, Lanraplenib + Gilteritinib (NCT05028751)
- 2024-08-07Also stopped (terminated): Kronos Bio, Lanraplenib + Gilteritinib (NCT05028751)
- 2024-01-10Results posted on the registry: Kronos Bio, Entospletinib + Placebo (NCT05020665)
- 2024-01-10Also stopped (terminated): Kronos Bio, Entospletinib + Placebo (NCT05020665)
- 2023-12-11Results posted on the registry: Rigel Pharmaceuticals, Fostamatinib Disodium (NCT02077192)
- 2023-09-18Results posted on the registry: Asana BioSciences, ASN002 (NCT03654755)
- 2023-09-18Also stopped (terminated): Asana BioSciences, ASN002 (NCT03654755)
- 2023-08-08Results posted on the registry: Alexey Danilov, MD, Entospletinib + Obinutuzumab (NCT03010358)
- 2023-05-25Results posted on the registry: Rigel Pharmaceuticals, Fostamatinib disodium + Placebo (NCT03764618)
- 2023-05-09Results posted on the registry: Asana BioSciences, ASN002 + Placebo Oral Tablet (NCT03728504)
- 2023-04-04Also stopped (terminated): Calithera Biosciences, Inc, Mivavotinib (NCT05319028)
- 2023-02-21Also stopped (withdrawn): Portola Pharmaceuticals, Cerdulatinib (NCT04021082)
- 2023-02-06Also stopped (suspended): Ascend Biopharmaceuticals Ltd, ASN-002 (NCT03208296)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision